W

WuXi XDC Cayman Inc
HKEX:2268

Watchlist Manager
WuXi XDC Cayman Inc
HKEX:2268
Watchlist
Price: 31.7 HKD
Market Cap: 38B HKD
Have any thoughts about
WuXi XDC Cayman Inc?
Write Note

WuXi XDC Cayman Inc
Cash Interest Paid

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

WuXi XDC Cayman Inc
Cash Interest Paid Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Interest Paid CAGR 3Y CAGR 5Y CAGR 10Y
W
WuXi XDC Cayman Inc
HKEX:2268
Cash Interest Paid
ÂĄ315k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Cash Interest Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Cash Interest Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Cash Interest Paid
ÂĄ207.5m
CAGR 3-Years
33%
CAGR 5-Years
105%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Cash Interest Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Genscript Biotech Corp
HKEX:1548
Cash Interest Paid
$3.4m
CAGR 3-Years
21%
CAGR 5-Years
86%
CAGR 10-Years
N/A
No Stocks Found

WuXi XDC Cayman Inc
Glance View

Market Cap
38B HKD
Industry
Life Sciences Tools & Services

WuXi XDC Cayman Inc. is an intriguing player in the biotechnology field, strategically positioned at the crossroads of innovation and precision. As a distinctive subsidiary under the umbrella of WuXi AppTec, it zeroes in on the burgeoning and highly specialized market of antibody-drug conjugates (ADCs). These ADCs are engineered to deliver chemotherapy drugs directly to cancer cells, offering a synthesis of traditional medicine's effectiveness with the pinpoint accuracy of modern biotechnology. This localized delivery aims to enhance therapeutic outcomes while minimizing adverse effects, a compelling value proposition amid rising consumer demand for more personalized cancer treatments. The company thrives through an integrated business model, presenting a suite of comprehensive services that span the entire ADC development lifecycle. It monetizes its expertise by offering clients a seamless pathway from research and development through to clinical manufacturing. Clients, which range from startup biotech firms to established pharmaceutical giants, engage WuXi XDC not only for its technical prowess but also for its capacity to expedite product pipelines. By managing complex supply chains and providing robust regulatory support, the company enables its clients to reduce time-to-market, ultimately maneuvering the intricate framework of drug development with finesse. Through this strategic approach, WuXi XDC has positioned itself as a critical partner in the ADC landscape, driving innovation and delivering value to both its clientele and stakeholders.

Intrinsic Value
30.29 HKD
Overvaluation 4%
Intrinsic Value
Price
W

See Also

What is WuXi XDC Cayman Inc's Cash Interest Paid?
Cash Interest Paid
315k CNY

Based on the financial report for Dec 31, 2023, WuXi XDC Cayman Inc's Cash Interest Paid amounts to 315k CNY.

What is WuXi XDC Cayman Inc's Cash Interest Paid growth rate?
Cash Interest Paid CAGR 1Y
5%

Over the last year, the Cash Interest Paid growth was 5%.

Back to Top